Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert Davis is active.

Publication


Featured researches published by Robert Davis.


Psychopharmacology | 1985

Continuous low-level apomorphine administration induces motor abnormalities and hallucinogen-like behaviors

Robert Davis; William W. Sant; Gaylord Ellison

Continuous low-level (0.825 mg/kg/h for 20 h) administration of AP through SC in-dwelling silicone reservoirs in the rat induced behavioral and biochemical changes that were similar to those induced by low levels (0.1 mg/kg) of acutely administered AP (decreased behavioral activity and decreased dopamine metabolism in the striatum). With longer periods of continuous AP exposure (40 h or more) the activity-depressing effects of low-level AP diminished. Concurrently a novel behavioral syndrome emerged characterized by limb flicks, body shakes, sudden orienting responses, and motor abnormalities, such as tremors of the jaw muscles, chewing movements, prominent tongue extensions, and body ‘tics’. This behavioral syndrome became more apparent following cessation of drug treatment. These novel behavioral changes, which were accompanied by increased behavioral responsiveness to acutely administered AP and amphetamine, were correlated with increased levels of dopamine, homovanillic acid, and 3,4-dihydroxyphenylacetic acid in the striatum but not the nucleus accumbens. This novel behavioral syndrome appears to reflect a rebound increase in dopaminergic mechanisms in striatum following their chronic suppression by low levels of AP.


Life Sciences | 1982

Picrotoxin-induced disruption of bidirectional active avoidance behavior and locomotor activity

Robert Davis

The effects of picrotoxin (0.75 and 1.5 mg/kg), an antagonist of GABA mediated chloride ion conductance changes, were examined on the acquisition and performance of a bidirectional active avoidance (BAA) response and on locomotor activity. Treatment with this agent disrupted both the acquisition and performance of this task and decreased locomotor activity. This picrotoxin-induced suppression of BAA was reversed by pretreatment with diazepam (2 mg/kg), d-amphetamine (d-AMP, 2.0 mg/kg) and lysergic acid diethylamide (LSD, 10 micrograms/kg) and was reversed partially by cinanserin (5 mg/kg) and methysergide (5 mg/kg). Picrotoxin-induced activity decreases in locomotor activity were antagonized by d-AMP, were partially reversed by LSD but were not reversed by methysergide. It is proposed that picrotoxin disrupts bidirectional active avoidance behavior by increasing the response suppressive effects of aversive stimuli and by inducing a general depression of motility.


Archive | 2013

Novel compositions and methods

Sharon Mates; Robert Davis; Kimberly E. Vanover; Lawrence P. Wennogle


Psychopharmacology | 2016

Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats

Gretchen L. Snyder; Jos Prickaerts; Marie-Louise G. Wadenberg; Lei Zhang; Hailin Zheng; Wei Yao; Sven Akkerman; Hongwen Zhu; Joseph P. Hendrick; Kimberly E. Vanover; Robert Davis; Peng Li; Sharon Mates; Lawrence P. Wennogle


Archive | 2011

Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives

Sharon Mates; Robert Davis; Lawrence P. Wennogle; Peng Li; John Tomesch; Qiang Zhang


Archive | 2015

Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders

Sharon Mates; Robert Davis; Lawrence P. Wennogle; Peng Li; John Tomesch; Qiang Zhang


Archive | 2014

Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity

Peng Li; Qiang Zhang; Robert Davis; Lawrence P. Wennogle


Archive | 2018

FUSED GAMMA CARBOLINES

Sharon Mates; Robert Davis; Peng Li; Lawrence P. Wennogle; Richard A. Lerner


Archive | 2015

Heterocycle fused gamma-carbolines for treatment of central nervous system disorders

Sharon Mates; Peng Li; Lawrence P. Wennogle; Robert Davis


Archive | 2015

SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA

Lawrence P. Wennogle; Robert Davis; Peng Li

Collaboration


Dive into the Robert Davis's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peng Li

Rockefeller University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Qiang Zhang

University of Medicine and Dentistry of New Jersey

View shared research outputs
Top Co-Authors

Avatar

Graham Buckton

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Mark Hooper

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge